SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...
The FDA authorized marketing of the first DNA test to help detect hundreds of genetic variants associated with cancer predisposition. The Invitae Common Hereditary Cancers Panel tests DNA in a blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results